Menu
Back to User profile » Professor Davide Croce
Papers published by Professor Davide Croce:
Co-Design as Enabling Factor for Patient-Centred Healthcare: A Bibliometric Literature Review
Silvola S, Restelli U, Bonfanti M, Croce D
ClinicoEconomics and Outcomes Research 2023, 15:333-347
Published Date: 17 May 2023
Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
Restelli U, Croce D, Pacelli V, Ciceri F, Girmenia C
Infection and Drug Resistance 2019, 12:1127-1138
Published Date: 8 May 2019
Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum]
Restelli U, Ceresoli GL, Croce D, Evangelista L, Maffioli LS, Gianoncelli L, Bombardieri E
Cancer Management and Research 2018, 10:613-614
Published Date: 27 March 2018
Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study
Restelli U, Ceresoli GL, Croce D, Evangelista L, Maffioli LS, Gianoncelli L, Bombardieri E
Cancer Management and Research 2017, 9:789-800
Published Date: 7 December 2017
Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D
ClinicoEconomics and Outcomes Research 2017, 9:569-571
Published Date: 27 September 2017
Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]
Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D
ClinicoEconomics and Outcomes Research 2017, 9:231-232
Published Date: 19 April 2017
Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D
ClinicoEconomics and Outcomes Research 2017, 9:173-179
Published Date: 1 March 2017